Brokerage Firm Rating Update on Illumina (ILMN)

Illumina (ILMN) : 15 analysts are covering Illumina (ILMN) and their average rating on the stock is 2.55, which is read as a Hold. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 10 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Illumina (ILMN) : Average target price received by Illumina (ILMN) is $152.1 with an expected standard deviation of $20.63. The most aggressive target on the stock is $180, whereas the most downbeat target is $115. 10 financial analysts are currently covering the stock.


Company shares have received an average consensus rating of Hold for the current week Also, Major Brokerage house, CL King downgrades its ratings on Illumina (NASDAQ:ILMN). According to the latest information available, the shares are now rated Neutral by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on August 22, 2016.

Illumina (NASDAQ:ILMN): stock was range-bound between the intraday low of $168.21 and the intraday high of $172.98 after having opened at $169.69 on Wednesdays session. The stock finally closed in the red at $169.69, a loss of -0.35%. The stock remained in the red for the whole trading day. The total traded volume was 607,839 shares. The stock failed to cross $172.98 in Wednesdays trading. The stocks closing price on Thursday was $170.18.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.